Funded Biotechnology Startups in Austria
Austria's biotechnology funding activity, across the 12 most recent rounds in this dataset, spans from pre-seed through Series D.
Austria's biotechnology funding activity, across the 12 most recent rounds in this dataset, spans from pre-seed through Series D. Seed rounds are the most common stage, representing six entries — including VALANX Biotech and Celeris Therapeutics in Graz, Arkeon Biotechnologies and Lignovations in Tulln, and Sarcura in Klosterneuburg. The only late-stage deal is Innovacell's undisclosed Series D, closed in Innsbruck in August 2025, the most recent round in the set.
Vienna accounts for three companies — Hookipa Pharma ($21M, December 2023), Brightmind.ai ($800K), and invIOs — but Steiermark and Niederosterreich together hold more entries than the capital. Disclosed round sizes range from $800K to $21M. Three rounds closed in the first eight months of 2025 alone, suggesting continued deal flow after a cluster of five rounds in 2023.
Most recent rounds
12 shownRelated listings
Frequently asked
What is the largest disclosed round among these Austrian biotech companies?
Hookipa Pharma's December 2023 raise of $21M is the largest disclosed amount in the dataset. Sarcura and Arkeon Biotechnologies each closed $7M Seed rounds — in Klosterneuburg and Tulln respectively — making them the next largest by disclosed size.
Which funding stage appears most often in these rounds?
Seed is the dominant stage, accounting for six of the twelve entries: aTension.life, Lignovations, VALANX Biotech, Sarcura, Arkeon Biotechnologies, and Celeris Therapeutics. There is one Pre-Seed (Graph Therapeutics), one Series D (Innovacell), and four rounds classified as Series Unknown.
Which Austrian cities show up most in recent biotech funding?
Vienna appears in three entries — Hookipa Pharma, Brightmind.ai, and invIOs — but Graz accounts for an equal three: VALANX Biotech, Briefcase Biotec, and Celeris Therapeutics. Klosterneuburg (Graph Therapeutics, Sarcura) and Tulln (Lignovations, Arkeon Biotechnologies) each have two entries, showing activity is spread well beyond the capital.
How much of the recent funding activity falls in 2025?
Three of the twelve rounds closed in 2025: Innovacell's Series D in August, aTension.life's $3M Seed in April, and Graph Therapeutics' $3M Pre-Seed in January. The prior year, 2024, has only one entry — Brightmind.ai's $800K round in May.
How many rounds have undisclosed amounts, and which companies are they?
Three rounds list undisclosed amounts: Innovacell (Series D, August 2025), invIOs (Series Unknown, September 2023), and Briefcase Biotec (Series Unknown, June 2023). The remaining nine disclosed rounds range from $800K to $21M.
Is there any late-stage activity, or is this predominantly early-stage funding?
The dataset is mostly early-stage. Innovacell's Series D in Innsbruck is the only clearly late-stage deal in the set. All other staged rounds are Seed or Pre-Seed, and four are unclassified Series Unknown.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.